Supernus Pharmaceuticals (SUPN) Gross Margin (2013 - 2025)

Supernus Pharmaceuticals (SUPN) has 13 years of Gross Margin data on file, last reported at 89.13% in Q4 2025.

• On a quarterly basis, Gross Margin rose 411.0% year-over-year to 89.13% in Q4 2025; TTM through Dec 2025 was 89.63%, a 140.0% increase from a year earlier, with the FY2025 full-year figure at 89.63%, up 140.0% from the prior year.
• Gross Margin for Q4 2025 stood at 89.13%, down from 90.13% in the prior quarter.
• Over the last five years, Gross Margin for SUPN reached as high as 90.13% in Q3 2025 and fell as low as 82.29% in Q2 2021.
• Historically, Gross Margin has averaged 87.6% across 5 years, with a median of 88.15% in 2023.
• Across the five-year window, Gross Margin plunged 705 bps in 2021 and soared 568 bps in 2022, its largest moves.
• Year by year, Gross Margin stood at 89.32% in 2021, then fell by 3 bps to 86.28% in 2022, then climbed by 2 bps to 88.06% in 2023, then retreated by 3 bps to 85.01% in 2024, then grew by 5 bps to 89.13% in 2025.
• Per Business Quant data, the three most recent Gross Margin figures were 89.13% in Q4 2025, 90.13% in Q3 2025, and 89.83% in Q2 2025.